Seres Therapeutics Inc
F:1S9

Watchlist Manager
Seres Therapeutics Inc Logo
Seres Therapeutics Inc
F:1S9
Watchlist
Price: 0.2 EUR
Market Cap: €30.3m

Net Margin

1 536.8%
Current
Improving
by 2 568%
vs 3-y average of -1 031.3%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
1 536.8%
=
Net Income
$5.4m
/
Revenue
$351k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
1 536.8%
=
Net Income
€5.4m
/
Revenue
$351k

Peer Comparison

Country Company Market Cap Net
Margin
US
Seres Therapeutics Inc
NASDAQ:MCRB
131.9m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
168.8B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.9B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.2B USD
Loading...

Market Distribution

Higher than 99% of companies in the United States of America
Percentile
99th
Based on 15 072 companies
99th percentile
1 536.8%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Seres Therapeutics Inc
Glance View

Market Cap
30.3m EUR
Industry
Biotechnology

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 333 full-time employees. The company went IPO on 2015-06-26. The firm is engaged in developing a class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The firm's lead product candidate, SER-109, is designed to reduce further recurrences of Clostridioides difficle infection (CDI). The company is also developing therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, a microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to reduce incidences of gastrointestinal infections, bloodstream infections and graft versus host disease (GvHD) in patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). In addition, using its microbiome therapeutics platform, the Company is developing SER-287 and SER-301 to treat ulcerative colitis (UC).

1S9 Intrinsic Value
0.003 EUR
Overvaluation 98%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
1 536.8%
=
Net Income
$5.4m
/
Revenue
$351k
What is Seres Therapeutics Inc's current Net Margin?

The current Net Margin for Seres Therapeutics Inc is 1 536.8%, which is above its 3-year median of -1 031.3%.

How has Net Margin changed over time?

Over the last 3 years, Seres Therapeutics Inc’s Net Margin has increased from -1 729.9% to 1 536.8%. During this period, it reached a low of -6 397% on Mar 31, 2023 and a high of 1 536.8% on Oct 30, 2025.

Back to Top